

PG3576USw
S/N 09/806,892

Remarks

The Examiner has rejected claim 32 under 35 USC 112 second paragraph as being indefinite. The Examiner notes that claim 32 refers to the "groups Y1R and Y2R as defined in claim," but the Examiner concludes that "it is unclear what constitutes Y1R and Y2R." The Examiner also notes that the preamble of claim 32 indicates the claim is directed toward a "method for assaying a chemical library." The Examiner points out there are no steps directed toward assaying a library and thus, the claim is indefinite.


Claim 32 has been amended to include the definition of the terms Y1R and Y2R given in claim 1 and thereby clarify the claim. The preamble has been amended to be consistent with the method as presently claimed.

Claim 32 stands rejected under 35 USC 102(b) as being anticipated by Lebl. Lebl does not include every limitation of the claimed method. Lebl does not disclose the Y1R and Y2R groups as defined in the claims and, more specifically, does not disclose the limitations relating to sensitizing group G. In light of the clarifications above, Applicants request the rejection be withdrawn.

Applicants submit claim 32 is in condition for allowance and request favorable reconsideration.

If the Examiner has any questions regarding this response, the Examiner is invited to contact the undersigned.

Respectfully submitted,



Michael M. Conger
Attorney for Applicants
Registration No. 43,562

Date: August 13, 2003
GlaxoSmithKline
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
Telephone: (919) 483-2474
Facsimile: (919) 483-7988